Medical Device Trials: Patient Recruitment Differences?
Praxis' director of marketing, Chris Layfield, offers insight into patient recruitment and developing a strategic recruitment plan when conducting medical device trials.
Medical Device Trials: Patient Recruitment Differences?
Chris Layfield, director of marketing at Brentwood, TN-based Praxis, told Applied Clinical Trials, “Like any trial, pharmaceutical or device, the process to developing a strategic recruitment plan is the same. One must fully understand the protocol and devise procedures to the extent that an accurate patient profile can be established. Without this, one cannot hope to effectively create a targeted reach program.”
Layfield explained after that is established, the appropriate primary, secondary and experiential research is done to determine how best to reach the persons identified in the profile – those that will be the most likely candidates for trial participation. Layfield offered this example; an acute situation where a new implantable device is being tested in heart attack patients. “If the decision to try the new device were to be needed within several hours or even less after a heart procedure then, information needs to be available to the treating physician and the family of the candidate at the time they present at the ER.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
